NAMS Stock — Price, Charts & Analysis

NewAmsterdam Pharma Company N.V. (NAMS) has no trailing P/E shown and a forward P/E of -17.72x. This places NAMS in not enough valuation data territory based on the valuation data currently available on Worldtickers.

NAMS trades with -17.72x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether NAMS looks overvalued or undervalued.

NAMS's P/E of -17.72x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

NAMS's trailing EPS is -$2.16 and forward EPS is -$1.57.

EPS, or earnings per share, shows how much profit NewAmsterdam Pharma Company N.V. generated for each share. NAMS's trailing EPS is -$2.16, and investors usually prefer EPS that is positive and growing over time.

NewAmsterdam Pharma Company N.V. has a market cap of $3.33B, making NAMS a mid-cap stock based on the current market value shown on Worldtickers.

NAMS's latest stock price on Worldtickers is $27.87. The latest move is $0.09 or 0.32%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

NAMS's quote includes a latest price of $27.87. The market open is $27.99. Previous close is $27.78. The intraday range is $27.66 to $28.35.

NAMS is up in the latest quote, with a move of $0.09 or 0.32%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

NAMS generated $7.12M in trailing revenue. Revenue growth is -80.70%, which helps show whether demand is expanding or slowing.

NAMS's revenue growth is -80.70%, which is a negative demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

No, NAMS does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -$259.50M.

Gross margin is 100.00%. Margins show how efficiently NewAmsterdam Pharma Company N.V. turns revenue into profit.

NewAmsterdam Pharma Company N.V. carries $82.00K and holds $633.85M in cash.

NAMS holds $633.85M on its balance sheet.

NAMS's book value per share is $5.37.

Institutions hold 105.85% of NAMS shares. Insiders hold 0.89% of shares. Ownership mix helps investors understand how much of NewAmsterdam Pharma Company N.V. is held by professional investors and company insiders.

NAMS has 119.54M shares outstanding. Float shares are 82.9M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for NAMS, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for NAMS is -$1.57. Revenue growth is -80.70%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

NAMS's trailing EPS is -$2.16. Forward EPS is -$1.57. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

NAMS is in the Healthcare sector. Its earnings multiple is -17.72x. Its latest displayed growth metric is -80.70%. Compare these figures with sector peers before deciding whether NewAmsterdam Pharma Company N.V. is stronger or weaker than average.

NAMS trades at $27.87. The stock trades at -17.72x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of NewAmsterdam Pharma Company N.V.'s fundamentals.

NAMS risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.11, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

NAMS should be compared with companies in Biotechnology. Its earnings multiple is -17.72x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

NewAmsterdam Pharma Company N.V. (NAMS) operates in Healthcare, specifically Biotechnology. NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharm

NAMS trades on NasdaqGM. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

NAMS stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

NewAmsterdam Pharma Company N.V.'s official website listed on Worldtickers is www.newamsterdampharma.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

NewAmsterdam Pharma Company N.V. employs about 100 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

NewAmsterdam Pharma Company N.V. is headquartered in Naarden, Netherlands. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

NAMS is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

NAMS has traded between $23.05 and $42.21 over the past 52 weeks. At $27.87, it is 33.97% below the high and 20.91% above the low. The 52-week range helps gauge long-term price momentum.

NAMS is below both its 50-day and 200-day moving averages, which is a common downtrend signal. Its 50-day moving average is $30.58 and its 200-day moving average is $33.15.

NAMS's RSI is 44.20. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

NAMS's latest RSI reading is 44.20, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for NAMS is near $25.74. Key resistance is near $31.29. Breaks above resistance or below support can change the short-term technical setup.

NAMS's nearest reported support level is $25.74. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

NAMS's nearest reported resistance level is $31.29. A breakout above resistance can improve momentum, especially when volume confirms the move.

NAMS trades about 1.14M shares daily on average. The latest displayed volume is 198.75K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

NAMS's MACD is 0.22, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

NAMS is below both its 50-day and 200-day moving averages, which is a common downtrend signal. RSI is 44.20 (neutral). MACD is bullish. Nearest support is around $25.74. Resistance is around $31.29. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $27.79 (0.28% from price). MA50 is $30.58 (-8.86% from price). MA200 is $33.15 (-15.92% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. NAMS's MA20 is $27.79. MA50 is $30.58. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

NAMS's pivot is near $27.91. Support is near $25.74. Resistance is near $31.29. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for NAMS is near $25.88. The next upper resistance zone is near $29.56. These levels help define risk and possible follow-through zones after a breakout or breakdown.

NAMS's Bollinger range is roughly $26.35 to $29.23. Band width is near 10.35%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

NAMS's ATR-based typical daily range is about 4.87%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 198.75K shares. Average volume is about 1.14M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

NAMS's all-time high shown on Worldtickers is $42.21. Its all-time low is $5.63. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

NAMS has a beta of 0.11, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.